Nmbr1stckpckr, imo it would be VERY helpful if

Nmbr1stckpckr,

imo it would be VERY helpful if we use his research and knowledge in out trial. Of course, we should use ANY information available out there. This is on a normal situation and much more so in a very fluid environment were solutions are needed pronto and the problem is mutating (pun intended).

The key is here:

Quote:

---

Using a multi-class deep neural network classifier to better fit our prediction model, we recapitulated a 100% precision, 100% recall and F1 score of 1 on the test set. Moreover, a first score specific for the chronic COVID-19 patients was defined as S1 = (IFN-γ + IL-2)/ CCL4-MIP-1β . Second, a score specific for the severe COVID-19 patients was defined as S2 = (10*IL-10 + IL-6) - (IL-2 + IL- . Severe cases are characterized by excessive inflammation and dysregulated T cell activation, recruitment, and counteracting activities. While chronic patients are characterized by a profile able to induce the activation of effector T cells with pro-inflammatory properties and the capacity of generating an effective immune response to eliminate the virus but without the proper recruitment signals to attract activated T cells.

---

As of late he has tweeted of "starting a new study using IncellDX CCR5 delta 2 assay across COVID disease continuum including Long Haulers", this, needless to say will impact us.

Also, as of late he has stressed the protective effect of the delta 2 allele in COVID adding more weight to the protective effect of CCR5/CCL5 axis the pathogenesis of this.

Not to mention a VERY important result of his tests: 25% of log haulers have low CD8%

Does it sound familiar ?? It should !!!. From Dr. Patterson paper:

CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells , and decreases SARS-CoV2 RNA in plasma by day 14 "



So, question: would Vyrologix-Leronlimab work ??? Do you see these beautiful %CD8 curves going up-up-up ????

YES !!!!